CA2424033A1 - Dispositif robotique automatise pour la cristallisation a controle dynamique de proteines - Google Patents
Dispositif robotique automatise pour la cristallisation a controle dynamique de proteines Download PDFInfo
- Publication number
- CA2424033A1 CA2424033A1 CA002424033A CA2424033A CA2424033A1 CA 2424033 A1 CA2424033 A1 CA 2424033A1 CA 002424033 A CA002424033 A CA 002424033A CA 2424033 A CA2424033 A CA 2424033A CA 2424033 A1 CA2424033 A1 CA 2424033A1
- Authority
- CA
- Canada
- Prior art keywords
- reagent
- chamber
- sample
- solution
- dynamic dialysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 148
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 147
- 238000002425 crystallisation Methods 0.000 title claims abstract description 115
- 230000008025 crystallization Effects 0.000 title claims abstract description 114
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 481
- 238000000034 method Methods 0.000 claims abstract description 141
- 239000012528 membrane Substances 0.000 claims abstract description 46
- 230000009466 transformation Effects 0.000 claims abstract description 19
- 238000000844 transformation Methods 0.000 claims abstract description 12
- 238000000502 dialysis Methods 0.000 claims description 275
- 239000000523 sample Substances 0.000 claims description 250
- 239000012530 fluid Substances 0.000 claims description 116
- 210000004027 cell Anatomy 0.000 claims description 99
- 239000013078 crystal Substances 0.000 claims description 86
- 238000012546 transfer Methods 0.000 claims description 83
- 230000007246 mechanism Effects 0.000 claims description 51
- 238000010899 nucleation Methods 0.000 claims description 42
- 230000006911 nucleation Effects 0.000 claims description 42
- 230000004044 response Effects 0.000 claims description 34
- 230000012010 growth Effects 0.000 claims description 33
- 238000004458 analytical method Methods 0.000 claims description 31
- 230000008859 change Effects 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 18
- 239000012488 sample solution Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 238000002356 laser light scattering Methods 0.000 claims description 16
- 239000003446 ligand Substances 0.000 claims description 16
- 238000005339 levitation Methods 0.000 claims description 14
- 239000006143 cell culture medium Substances 0.000 claims description 12
- 239000002609 medium Substances 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 230000001376 precipitating effect Effects 0.000 claims description 12
- 230000004888 barrier function Effects 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 9
- 230000007773 growth pattern Effects 0.000 claims description 9
- 230000004060 metabolic process Effects 0.000 claims description 9
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 9
- 238000005086 pumping Methods 0.000 claims description 9
- 230000003068 static effect Effects 0.000 claims description 9
- 230000005484 gravity Effects 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 5
- 238000000235 small-angle X-ray scattering Methods 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 230000005292 diamagnetic effect Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000002491 ultra-small angle X-ray scattering Methods 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 238000002090 ultra small angle neutron scattering Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 1
- 230000026676 system process Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 155
- 230000008569 process Effects 0.000 description 49
- 210000001772 blood platelet Anatomy 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 239000000376 reactant Substances 0.000 description 21
- 238000012544 monitoring process Methods 0.000 description 18
- 238000000429 assembly Methods 0.000 description 16
- 230000000712 assembly Effects 0.000 description 16
- 239000012460 protein solution Substances 0.000 description 14
- 230000005291 magnetic effect Effects 0.000 description 13
- 230000003287 optical effect Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 238000012216 screening Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- -1 atom compound Chemical class 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000002050 diffraction method Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000001553 co-assembly Methods 0.000 description 3
- 230000003436 cytoskeletal effect Effects 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004886 process control Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 238000001998 small-angle neutron scattering Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BJSKBZUMYQBSOQ-UHFFFAOYSA-N Jeffamine M-600 Chemical compound COCCOCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)OCC(C)N BJSKBZUMYQBSOQ-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 108700002791 mouse Cd244a Proteins 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000010903 primary nucleation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/14—Investigating or analyzing materials by the use of thermal means by using distillation, extraction, sublimation, condensation, freezing, or crystallisation
- G01N25/147—Investigating or analyzing materials by the use of thermal means by using distillation, extraction, sublimation, condensation, freezing, or crystallisation by cristallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
La présente invention concerne un appareil et des procédés permettant le contrôle indépendant des transformations dynamiques provoquées par des réactifs d'une pluralité d'échantillons comprenant des protéines en cours de cristallisation et des cellules en cours de culture. L'invention propose un dispositif robotique automatique qui améliore la cristallisation des protéines en production élevée, au moyen de réservoirs de réactifs (28) reliés à des enceintes de réactifs (40), avec des chambres d'échantillons (44) communiquant avec les réservoirs de réactifs (28) via une membrane semi-perméable.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23592800P | 2000-09-28 | 2000-09-28 | |
| US23592200P | 2000-09-28 | 2000-09-28 | |
| US23592300P | 2000-09-28 | 2000-09-28 | |
| US23592700P | 2000-09-28 | 2000-09-28 | |
| US60/235,927 | 2000-09-28 | ||
| US60/235,922 | 2000-09-28 | ||
| US60/235,923 | 2000-09-28 | ||
| US60/235,928 | 2000-09-28 | ||
| PCT/US2001/030454 WO2002026342A1 (fr) | 2000-09-28 | 2001-09-28 | Dispositif robotique automatise pour la cristallisation a controle dynamique de proteines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2424033A1 true CA2424033A1 (fr) | 2002-04-04 |
Family
ID=27499824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002424033A Abandoned CA2424033A1 (fr) | 2000-09-28 | 2001-09-28 | Dispositif robotique automatise pour la cristallisation a controle dynamique de proteines |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1444023A1 (fr) |
| AU (1) | AU2002211293A1 (fr) |
| CA (1) | CA2424033A1 (fr) |
| GB (1) | GB2384729A (fr) |
| WO (1) | WO2002026342A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8403888B2 (en) | 2010-04-15 | 2013-03-26 | Teneo Innovations Inc. | Device and electronic controller for syringe piston control |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818060B2 (en) | 1999-08-02 | 2004-11-16 | Emerald Biostructures, Inc. | Robot for mixing crystallization trial matrices |
| US6860940B2 (en) | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
| WO2004097707A2 (fr) * | 2003-04-25 | 2004-11-11 | Novartis Ag | Systeme et procede d'analyse d'images entierement automatisee et assistee par robot pour des essais de genotoxicite in vitro et in vivo |
| US7463982B2 (en) | 2004-12-22 | 2008-12-09 | Lawrence Livermore National Security, Llc | Liquid class predictor for liquid handling of complex mixtures |
| GB2554334A (en) | 2016-05-17 | 2018-04-04 | Tap Biosystems Phc Ltd | Automated bioprocess development |
| JP6797717B2 (ja) * | 2017-03-02 | 2020-12-09 | 千代田化工建設株式会社 | タンパク質の結晶化方法および結晶化装置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62106000A (ja) * | 1985-10-30 | 1987-05-16 | Fujitsu Ltd | 生体高分子結晶自動作製装置 |
| FR2604917B1 (fr) * | 1986-10-09 | 1989-01-27 | Aerospatiale | Procede, cellule et dispositif de cristallogenese, notamment par vaisseau spatial |
| US5013531A (en) * | 1990-08-31 | 1991-05-07 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Macromolecular crystal growing system |
| JP2740375B2 (ja) * | 1990-10-25 | 1998-04-15 | 富士通株式会社 | 生体高分子結晶化装置 |
| US5641681A (en) * | 1995-04-17 | 1997-06-24 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Device and method for screening crystallization conditions in solution crystal growth |
| EP0913507A4 (fr) * | 1996-07-15 | 2002-03-13 | Sumitomo Metal Ind | Equipement de croissance de cristaux et procede pour la croissance de cristaux utilisant cet equipement |
| US5961934A (en) * | 1998-02-18 | 1999-10-05 | Biospace International Inc. | Dynamically controlled crystallization method and apparatus and crystals obtained thereby |
-
2001
- 2001-09-28 WO PCT/US2001/030454 patent/WO2002026342A1/fr not_active Ceased
- 2001-09-28 GB GB0309333A patent/GB2384729A/en not_active Withdrawn
- 2001-09-28 EP EP01979319A patent/EP1444023A1/fr not_active Withdrawn
- 2001-09-28 CA CA002424033A patent/CA2424033A1/fr not_active Abandoned
- 2001-09-28 AU AU2002211293A patent/AU2002211293A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8403888B2 (en) | 2010-04-15 | 2013-03-26 | Teneo Innovations Inc. | Device and electronic controller for syringe piston control |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0309333D0 (en) | 2003-06-04 |
| WO2002026342A9 (fr) | 2004-04-22 |
| EP1444023A1 (fr) | 2004-08-11 |
| GB2384729A (en) | 2003-08-06 |
| AU2002211293A1 (en) | 2002-04-08 |
| WO2002026342A1 (fr) | 2002-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6596081B1 (en) | Dynamically controlled crystallization method and apparatus and crystals obtained thereby | |
| EP1119654B1 (fr) | Plateau de cristallisation | |
| US20040033166A1 (en) | Automated robotic device for dynamically controlled crystallization of proteins | |
| US6818060B2 (en) | Robot for mixing crystallization trial matrices | |
| US20060281143A1 (en) | Method and apparatus for automatic cell and biological sample preparation and detection | |
| US20150322479A1 (en) | Apparatus and method for quantification of replicative lifespan and observation of senescene | |
| EP1177029B1 (fr) | Station de travail haute capacite de criblage de formes cristallines et son utilisation | |
| US6860940B2 (en) | Automated macromolecular crystallization screening | |
| CA2120744A1 (fr) | Dispositif formant des cristaux et systeme de cristallisation automatise | |
| US20110218120A1 (en) | Ordered two- and three-dimensional structures of amphiphilic molecules | |
| US20030049642A1 (en) | Screening system | |
| US20020100411A1 (en) | Applying x-ray topography and diffractometry to improve protein crystal growth | |
| CA2424033A1 (fr) | Dispositif robotique automatise pour la cristallisation a controle dynamique de proteines | |
| US20110195515A1 (en) | Capillary Plate and Method for Growth and Analysis of Macromolecular Crystals | |
| US7008599B1 (en) | High throughput crystal form screening workstation and method of use | |
| US9382639B2 (en) | Device and method for crystallizing inorganic or organic substances | |
| US20030153089A1 (en) | Screening crystallization conditions of organic compounds | |
| Liu et al. | Imaging protein crystal growth behaviour in batch cooling crystallisation | |
| EP1059976A1 (fr) | Procede et appareil de cristallisation a commande dynamique et cristaux obtenus au moyen de ceux-ci | |
| WO2017132637A2 (fr) | Appareil et procédé pour surveiller une pluralité d'échantillons de fluide | |
| Stokes et al. | High-throughput methods for electron crystallography | |
| WO2006099890A1 (fr) | Procede et dispositif permettant de promouvoir la croissance cristalline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20070928 |